CA3022654A1 - Methods for predicting the usefulness of proteins or protein fragments for immunotherapy - Google Patents

Methods for predicting the usefulness of proteins or protein fragments for immunotherapy Download PDF

Info

Publication number
CA3022654A1
CA3022654A1 CA3022654A CA3022654A CA3022654A1 CA 3022654 A1 CA3022654 A1 CA 3022654A1 CA 3022654 A CA3022654 A CA 3022654A CA 3022654 A CA3022654 A CA 3022654A CA 3022654 A1 CA3022654 A1 CA 3022654A1
Authority
CA
Canada
Prior art keywords
protein
fragment
cells
immunotherapy
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3022654A
Other languages
English (en)
French (fr)
Inventor
Mathias VORMEHR
Ugur Sahin
Barbara Schrors
Martin Lower
Sebastian BOEGEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Biontech SE
Original Assignee
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Biontech RNA Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH, Biontech RNA Pharmaceuticals GmbH filed Critical TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Publication of CA3022654A1 publication Critical patent/CA3022654A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3022654A 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy Pending CA3022654A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (en) 2016-05-13 2016-05-13 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EPPCT/EP2016/060897 2016-05-13
PCT/EP2017/061196 WO2017194610A1 (en) 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (1)

Publication Number Publication Date
CA3022654A1 true CA3022654A1 (en) 2017-11-16

Family

ID=55971007

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3022654A Pending CA3022654A1 (en) 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Country Status (27)

Country Link
US (2) US12153041B2 (https=)
EP (3) EP4411376A3 (https=)
JP (5) JP7529381B2 (https=)
KR (3) KR20220020993A (https=)
CN (1) CN109073637A (https=)
AU (2) AU2017264546B2 (https=)
BR (1) BR112018073221A2 (https=)
CA (1) CA3022654A1 (https=)
CY (1) CY1123520T1 (https=)
DK (2) DK3792628T3 (https=)
ES (2) ES2826480T3 (https=)
FI (1) FI3792628T3 (https=)
HR (2) HRP20240704T1 (https=)
HU (2) HUE067497T2 (https=)
IL (2) IL300841A (https=)
LT (2) LT3455625T (https=)
MA (1) MA43794B1 (https=)
MD (1) MD3455625T2 (https=)
MX (2) MX393653B (https=)
PL (2) PL3455625T3 (https=)
PT (2) PT3792628T (https=)
RS (2) RS65568B1 (https=)
SG (1) SG11201808495SA (https=)
SI (2) SI3792628T1 (https=)
SM (2) SMT202400232T1 (https=)
WO (2) WO2017194170A1 (https=)
ZA (1) ZA201805809B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL260030B2 (en) 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EP3933408A1 (en) 2017-05-30 2022-01-05 Nant Holdings IP LLC Circulating tumor cell enrichment using neoepitopes
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
TWI894138B (zh) * 2019-03-06 2025-08-21 美商西雅圖項目公司 利用ii 類mhc 模型鑑別新抗原
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN111487399B (zh) * 2020-03-26 2021-09-17 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
DK1276896T3 (da) * 2000-04-28 2010-10-18 Mannkind Corp Epitop-synkronisering i antigen-præsenterende celler
CA2415902A1 (en) 2000-07-10 2002-01-17 Xencor Protein design automation for designing protein libraries with altered immunogenicity
JP4900884B2 (ja) * 2000-07-31 2012-03-21 株式会社グリーンペプタイド 腫瘍抗原
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
TW200413539A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
WO2006105255A2 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
JP2009273377A (ja) * 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
CA2755983A1 (en) 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response
AU2010310468A1 (en) * 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP2714730A1 (en) * 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
CA3060569A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
AU2018279627B2 (en) 2017-06-09 2023-08-10 Seattle Project Corp. Neoantigen identification, manufacture, and use
US20200363414A1 (en) 2017-09-05 2020-11-19 Gritstone Oncology, Inc. Neoantigen Identification for T-Cell Therapy
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
EP3759131A4 (en) 2018-02-27 2021-12-01 Gritstone bio, Inc. NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS

Also Published As

Publication number Publication date
ES2826480T3 (es) 2021-05-18
PT3455625T (pt) 2020-10-22
HUE052240T2 (hu) 2021-04-28
IL262680B1 (en) 2023-04-01
RS61071B1 (sr) 2020-12-31
IL300841A (en) 2023-04-01
CN109073637A (zh) 2018-12-21
JP2022081492A (ja) 2022-05-31
AU2017264546B2 (en) 2022-04-28
US20250244311A1 (en) 2025-07-31
JP2024096712A (ja) 2024-07-17
EP3455625B1 (en) 2020-09-02
WO2017194610A1 (en) 2017-11-16
PL3792628T3 (pl) 2024-07-15
AU2022209286A1 (en) 2022-08-25
ZA201805809B (en) 2020-12-23
HUE067497T2 (hu) 2024-10-28
KR20240146087A (ko) 2024-10-07
KR102358620B1 (ko) 2022-02-07
EP3792628B1 (en) 2024-04-24
EP4411376A3 (en) 2025-03-19
FI3792628T3 (fi) 2024-06-07
KR20190008218A (ko) 2019-01-23
HRP20201671T1 (hr) 2021-03-05
RU2018137721A3 (https=) 2020-08-25
EP3792628A2 (en) 2021-03-17
US12153041B2 (en) 2024-11-26
DK3455625T3 (da) 2020-10-26
PL3455625T3 (pl) 2021-01-25
JP7529381B2 (ja) 2024-08-06
HRP20240704T1 (hr) 2024-09-27
LT3792628T (lt) 2024-06-25
EP3455625A1 (en) 2019-03-20
BR112018073221A2 (pt) 2019-02-19
SI3792628T1 (sl) 2024-08-30
MX2018013081A (es) 2019-01-24
DK3792628T3 (da) 2024-06-17
AU2017264546A1 (en) 2018-10-18
IL262680B2 (en) 2023-08-01
MX2022007902A (es) 2022-07-21
PT3792628T (pt) 2024-06-18
SMT202000622T1 (it) 2021-01-05
IL262680A (en) 2018-12-31
US20190178871A1 (en) 2019-06-13
JP2024112805A (ja) 2024-08-21
SI3455625T1 (sl) 2021-01-29
JP2024160216A (ja) 2024-11-13
RS65568B1 (sr) 2024-06-28
MX393653B (es) 2025-03-24
SMT202400232T1 (it) 2024-07-09
SG11201808495SA (en) 2018-10-30
MD3455625T2 (ro) 2020-12-31
EP3792628A3 (en) 2021-05-19
CY1123520T1 (el) 2022-03-24
EP4411376A2 (en) 2024-08-07
ES2980781T3 (es) 2024-10-03
MA43794B1 (fr) 2020-12-31
KR20220020993A (ko) 2022-02-21
MA43794A (fr) 2019-03-20
LT3455625T (lt) 2021-01-11
RU2018137721A (ru) 2020-06-15
WO2017194170A1 (en) 2017-11-16
JP2019520554A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
US20250244311A1 (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR102560750B1 (ko) 면역요법을 위한 질환 특이적 아미노산 변형의 유용성을 예측하는 방법
KR20240095527A (ko) 예방접종에 유용한 t 세포 에피토프의 예측 방법
IL264203B2 (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
HK40114873A (en) Methods for predicting the usefulness of neoantigens for immunotherapy
HK40049190A (en) Methods for predicting the usefulness of neoantigens for immunotherapy
HK40049190B (en) Methods for predicting the usefulness of neoantigens for immunotherapy
RU2782336C2 (ru) Способы прогнозирования применимости белков или белковых фрагментов для иммунотерапии
HK1262104A1 (en) Methods for predicting the usefulness of neoantigens for immunotherapy
HK1262104B (en) Methods for predicting the usefulness of neoantigens for immunotherapy
NZ787614A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
HK40002506A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
HK40020601A (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220503

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240906

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250506

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250506

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251017

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421